Chilgok Kyungpook National University Medical Center Station is a station of the Daegu Metro Line 3 in Gugu-dong, Buk District, Daegu, South Korea.

During the past decade, Kyungpook National University Medical Center Chilgok Hospital conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 5 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 4 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kyungpook National University Medical Center Chilgok Hospital" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Arena Pharmaceuticals" with 2 trials sponsored, "Bukwang Pharmaceutical" with 2 trials sponsored, "Boryung Pharmaceutical Co., Ltd" with 1 trials sponsored and "JW Pharmaceutical" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kyungpook National University Medical Center Chilgok Hospital" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Asan Medical Center" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Gangnam Severance Hospital" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Kyungpook National University Medical Center Chilgok Hospital" are "Ulcerative Colitis" (5 trials), "Crohn's Disease" (2 trials), "Hepatitis B" (2 trials), "Breast Cancer" (1 trials) and "COVID-19" (1 trials). Many other conditions were trialed in "Kyungpook National University Medical Center Chilgok Hospital" in a lesser frequency.

Most popular intervention types in "Kyungpook National University Medical Center Chilgok Hospital" are "Drug" (17 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Mirikizumab" (4 trials), "Etrasimod" (3 trials), "Abemaciclib" (2 trials) and "(fimasartan and linagliptin) x 7days" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kyungpook National University Medical Center Chilgok Hospital" are 15 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Kyungpook National University Medical Center Chilgok Hospital". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Kyungpook National University Medical Center Chilgok Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Kyungpook National University Medical Center Chilgok Hospital, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".